CONCLUSION OF DEVELOPMENT COLLABORATION AGREEMENT FOR OPDIVO® (NIVOLUMAB) AND LENVIMA® (LENVATINIB MESYLATE) COMBINATION THERAPY FOR TREATMENT OF HEPATOCELLULAR CARCINOMA 20170908 CONCLUSION OF DEVELOPMENT COLL Friday September 8th, 2017By Tokio X'press JPN, Pharmaceutical ONO
Long-Term Analysis of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival in Patients with Relapsed Multiple Myeloma News Release 20170901 Long-Term Analysis of Phase 3 Saturday September 2nd, 2017By Tokio X'press JPN, Pharmaceutical ONO
Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan News Release 20170901 Ono and Seikagaku Reach a Defi Friday September 1st, 2017By Tokio X'press JPN, Pharmaceutical ONO
Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indications of Advanced Renal Cell Carcinoma, Relapsed or Progressed Classical Hodgkin Lymphoma, Recurrent or Metastatic Head and Neck, Locally Advanced or Metastatic Urothelial Carcinoma, and Unresectable or Metastatic Melanoma in Combination with Ipilimumab in South Korea News Release 20170830 Opdivo® (Nivolum Thursday August 31st, 2017By Tokio X'press Pharmaceutical ONO
